Table 1 Basic characteristics of included studies in this meta-analysis
Author | Year | Country | Sample size | Study period | Age (year) Median (range) | Gender (M/F) | Tumor grade | Histological type | Treatment | Cut-off value | Cut-off determination | Follow-up (month) Median (range) | Survival outcome | Survival analysis | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zhou, X. W | 2016 | China | 84 | 2013–2014 | 53 (43–62) | 50/34 | IV | GBM | Surgery | 4.37 | X-tile | 1–40 | OS | Univariate | 8 |
Wang, P. F | 2017 | China | 166 | 2009–2014 | 52 (18–80) | 96/70 | IV | GBM | Surgery | 3.7 | X-tile | 1–45 | OS | Univariate | 7 |
Bao, Y | 2018 | China | 219 | 2012–2017 |  ≥ 50 years: 146  < 50 years: 73 | 124/95 | I–IV | Glioma | Surgery | 3.7 | ROC curve | 1–60 | OS | Multivariate | 8 |
He, Z. Q | 2019 | China | 154 | 2001–2016 | 40 | 92/62 | III | Glioma | Mixed | 4.33 | ROC curve | 1–160 | OS | Univariate | 9 |
Zhang, Z. Y | 2019 | China | 592 | 2011–2016 | 42 | 335/257 | II–IV | Glioma | Surgery | 2.94 | X-tile | 32 | OS | Univariate | 8 |
Chim, S. T | 2021 | Australia | 64 | 1989–2018 | 51.5 | 44/20 | II–IV | Glioma | Mixed | 2.86 | ROC curve | 1–275 | OS | Univariate | 7 |
He, Q | 2021 | China | 105 | 2013–2019 | 50 (18–79) | 57/48 | III–IV | Glioma | Surgery | 5.0 | ROC curve | 1–80 | OS | Univariate | 8 |
Madhugiri, V. S | 2021 | India | 408 | 2007–2017 | 55 | 280/128 | IV | GBM | Surgery | 1.87 | X-tile | 1–113 | PFS | Univariate | 8 |
Xie, T | 2021 | China | 318 | 2001–2014 | 44 (5–78) | 194/124 | III–IV | Glioma | Mixed | 3.86 | ROC curve | 1–180 | OS, PFS | Univariate | 9 |
Yan, P | 2021 | China | 162 | 2012–2018 | 45 (7–82) | 88/74 | II–IV | Glioma | Mixed | 4.26 | ROC curve | 1–96 | OS | Univariate | 7 |
Chen, X. Y | 2022 | China | 199 | 2015–2020 |  < 60 years: 143  ≥ 60 years: 56 | 111/88 | III–IV | Glioma | Mixed | 4.47 | ROC curve | 1–30 | OS | Univariate | 8 |
Qi, Z | 2022 | China | 214 | 2001–2013 | 41 (5–79) | 131/83 | II–III | Glioma | Mixed | 4.81 | ROC curve | 1–144 | OS | Univariate | 7 |
Shi, X | 2022 | China | 232 | 2014–2018 |  < 65 years: 193  ≥ 65 years: 39 | 127/105 | IV | GBM | Mixed | 2.78 | ROC curve | 1–70 | OS, PFS | Univariate | 8 |
Stoyanov, G. S | 2022 | Bulgaria | 22 | 2018–2021 | 66 (50–86) | 15/7 | IV | GBM | Mixed | 2.22 | ROC curve | 8 (1–26) | OS | Univariate | 8 |
Yang, C | 2022 | China | 187 | 2016–2019 | 50 (21–81) | 111/76 | II–IV | Glioma | Mixed | 2.3 | ROC curve | 1–50 | OS | Multivariate | 7 |
Duan, X | 2023 | China | 281 | 2015–2018 |  ≤ 65 years: 223  > 65 years: 58 | 155/126 | IV | GBM | Mixed | 3.57 | ROC curve | 19 (3.5–63) | OS | Univariate | 8 |